Patents by Inventor Baoling Ying

Baoling Ying has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS
    Publication number: 20240116972
    Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.
    Type: Application
    Filed: November 15, 2023
    Publication date: April 11, 2024
    Inventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
  • 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
    Patent number: 11858956
    Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 2, 2024
    Assignees: Southern Research Institute, Oregon Health & Science University, Washington University in St. Louis, Board of Regents, The University of Texas System
    Inventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
  • 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS
    Publication number: 20220204545
    Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 30, 2022
    Inventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
  • Adenovirus replication-competent vectors expressing trail
    Publication number: 20040213764
    Abstract: The present invention provides replication-competent Adenoviral vectors that express TRAIL and ADP. In a particular aspect, TRAIL and/or ADP are highly expressed using the Adenovirus major late promoter or other promoter. Methods of treating hyperproliferative disorders using such vectors, alone or in combination with secondary therapies, also are described.
    Type: Application
    Filed: March 26, 2004
    Publication date: October 28, 2004
    Inventors: William Wold, Ann Tollefson, Baoling Ying